|Bid||49.81 x 1000|
|Ask||49.71 x 1100|
|Day's range||49.18 - 50.85|
|52-week range||41.45 - 61.71|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||9.52|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||1.60 (3.14%)|
|Ex-dividend date||03 Nov 2022|
|1y target est||54.78|
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
NEW YORK & CAMBRIDGE, Mass., December 06, 2022--Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication. This program will expand Pfizer’s innovative anti-infective p